Endothelial precursor cells home to a vascularized tissue engineering chamber by application of the angiogenic chemokine CXCl12 by Simcock, Jeremy et al.
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Tissue engineering of vascularized constructs has great utility in reconstructive surgery. While we have been
successful in generating vascularized granulation-like tissue and adipose tissue in an in vivo tissue engineering
chamber, production of other differentiated tissues in a stable construct remains a challenge. One approach is to
utilize potent differentiation factors, which can influence the base tissue. Endothelial precursor cells (EPCs) have
the ability to both carry differentiation factors and home to developing vasculature. In this study, proof-of-
principle experiments demonstrate that such cells can be recruited from the circulation into an in vivo tissue
engineering chamber. CXC chemokine ligand 12 (CXCL12)=stromal cell–derived factor 1 was infused into the
chamber through Alzet osmotic pumps and chamber cannulation between days 0 and 7, and facilitated re-
cruitment of systemically inoculated exogenous human EPCs injected on day 6. CXCL12 infusion resulted in an
eightfold increase in EPC recruitment, 2 ( p¼ 0.03) and 7 days postinfusion ( p¼ 0.008). Delivery of chemotactic=
proliferation and=or differentiation factors and appropriately timed introduction of effective cells may allow us
to better exploit the regenerative potential of the established chamber construct.
Introduction
Vascularized tissue engineering (VTE) is the creationof new tissue that has an intrinsic blood supply.1 It is a
field that has great potential in providing the basis for solid
organ engineering and for the reconstruction of large soft
tissue defects. We have developed a model of VTE based on
an arteriovenous loop (AVL) placed within a polycarbonate
chamber in the groin of the rat, from which a fibrin-rich
matrix exudes soon after AVL formation, providing a scaf-
fold for the spontaneous growth of a richly vascular fibrous
tissue that is stable for at least 16 weeks,2–5 and can be re-
moved from the chamber without detriment (Dolderer J. and
Abberton K.M., manuscript in preparation).
To enhance the utility of VTE, the growing tissue may be
manipulated by either the introduction of additional cell
types and=or chemotactic, growth, or differentiation factors.
One such chemotactic factor is CXC chemokine ligand 12
(CXCL12), an angiogenic chemotactic cytokine previously
called stromal cell–derived factor-1 (SDF-1).6
As an angiogenic chemokine, CXCL12 has important ef-
fects on new blood vessel development. These are both on
endogenous angiogenesis (directly and via secondary cyto-
kines such as vascular endothelial growth factor-A [VEGF-
A]7,8) and vasculogenesis—the formation of blood vessels
from endothelial precursor cells (EPCs).9,10 EPCs have been
shown to move from the bone marrow, circulate in the
bloodstream, and differentiate into mature endothelial cells
in situ to contribute to neovascularization.
EPCs homing to areas of neovascularization require ex-
pression of CXCR4 on their cell surface and the presentation
of CXCL12 in the target tissue.11–16 CXCL12 may enhance
VTE endpoints by increasing blood vessel growth (by an-
giogenesis and vasculogenesis) and by enhancing the hom-
ing of EPCs to the growing tissue.
The aim of this study was to analyze the effects of
CXCL12 on a vascularized tissue construct, particularly
the homing of EPCs. We assessed the tissue effects by
histomorphometric analysis to quantify any differences
seen. Immunohistochemistry was utilized to delineate the
endothelial-lined blood vessels and leucocyte populations
within the tissue. The effects of CXCL12 at a molecular level
were analyzed by quantitative RNA determination of the
inflammatory chemokine CXCL1, CXCL12 itself, and the
angiogenic growth factor VEGF. Finally, fluorescently la-
beled EPCs were tracked to the tissue construct to determine
the effect of CXCL12 on the incorporation of EPCs as this
tissue grows.
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Materials and Methods
Animal experiments
Nude (CBH=Rnu=nu) rats weighing 200–250 g (Animal
Resources Centre, Murdoch University, WA) were housed in
microisolator cages. Animal care was in accordance with
the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes (NH&MRC, sixth edition, 1997), and
experiments were approved by the Animal Ethics Commit-
tee, St. Vincent’s Hospital, Melbourne.
The VTE model used was essentially as described previ-
ously.1,2,5 Under general anesthesia (intraperitoneal keta-
mine [75mg=kg; Parnell Labs Pty, NSW, Australia] and
xylazine [10mg=kg; Troy Labs Pty, NSW, Australia]) an AVL
was formed from a length of left femoral vein micro-
surgically anastomosed between the right femoral vessels
and placed within a 0.5mL volume polycarbonate chamber
(made by the Department of Chemical and Biomolecular
Engineering, University of Melbourne) subcutaneously in the
right groin. The opening of the chamber was placed superi-
orly and attached to the inguinal ligament, and the femoral
vessels passed through this opening allowing the whole of
the AVL to lie within the chamber.
A CXCL12-containing pump was implanted in the sub-
cutaneous right flank with a catheter passing immediately
superficial to the femoral vessels, through the opening of the
polycarbonate chamber and terminating at the apex of the
AVL within the chamber (Fig. 1a). Recombinant human
stromal cell–derived factor-1a (SDF-1a=CXCL12, #557912;
BD Biosciences, San Diego, CA) was diluted in 0.1% bovine
serum albumin (BSA; CSL, Parkville, Victoria, Australia) to a
concentration of 10 mg=mL. This was loaded into an Alzet
microosmotic pump (Model 1007D; Durect, Cupertino, CA)
according to the manufacturer’s instructions. The specifica-
tions of the pumps were provided by the manufacturer to be
a mean pumping rate of 0.51 mL=h (SD¼ 0.03 mL=h) and a
mean fill volume of 96mL (SD¼ 2mL). The dimensions of the
pump were approximately a 1.5-cm-long, 5-mm-wide cylin-
der with rounded corners, and a catheter approximately 5 cm
long (Fig. 1c). The vinyl catheter tubing contained a volume
of 14.9 mL. Therefore, taking into account the overnight pre-
soaking and the residual volume of the catheter, the pump
would release a total of 1mg of CXCL12 protein over a pe-
riod of 7 days postoperatively. Human EPCs were injected
intracardially on day 6. At the conclusion of animal experi-
ments using pumps, the pumps were removed from the
animal and checked to ascertain that they were working. All
pumps were working at the conclusion of experiments.
Animals were divided into 7 groups and each group
comprised four animals. Four groups (as in Table 1) were
harvested 2 days following injection of EPCs, and 3 groups (as
Groups 2, 3 and 4 in Table 1) were harvested at 7 days fol-
lowing EPC injection. Tissue harvest was therefore 8 or 13
days after creation of the AVL chamber model (Fig. 1b). The
contents of the chamber were measured for weight and vol-
ume displacement.17 The tissue was sliced and one slice im-
mediately immersed in liquid nitrogen (for RNA anaylis). The
remaining slices were placed in fresh 4% paraformaldehyde
fixative for 8-12 h before histological processing.
EPC preparation, labeling, and injection
Human EPCs were provided by the laboratory of Prof.
Silviu Itescu, University of Melbourne, Department of
Medicine, St. Vincent’s Hospital, Melbourne. The cells were
retrieved by leucophoresis of patients following up to 3 days
of granulocyte colony-stimulating factor stimulation of the
bone marrow by daily subcutaneous injection. Cell sorting
was by magnetic affinity cell sorting using the CD34 Pro-
genitor Cell Isolation Kit (#467-02; Miltenyi Biotec, Auburn,
CA) resulting in a >96% CD34þ purity.18 The cells were
stored frozen until required for experimental use, at which
time the viable cells were counted by the Typan Blue ex-
clusion method. Cells from single individual patients were
injected into individual rats; that is, EPC samples were not
pooled for intracardiac injection.
Cell labeling immediately prior to injection was performed
with 3mg of the fluorescent cell trackers CM-DiI (#C-7000;
Molecular Probes, Eugene, OR) for every 1106 cells of cell
suspension at a concentration of 1106 cells=mL of phos-
phate-buffered saline (PBS) for 5min at 378C followed by a
further 15min on ice. The cells were then washed three times
with PBS (centrifuged at 750 g for 10min). The cell pellet was
resuspended at a concentration of 1106 cells=0.1mL in sa-
line for injection.
Uniform staining of cells was confirmed on aZeiss Axioskop
2 microscope with a rhodamine band-pass filter set using an
excitation filter wavelength of 546nm and emission filter
wavelength of 590nm (Zeiss block 15). Membrane-bound CM-
DiI has an absorption maximum of 553nm, an excitation co-
efficient of 134, and an emission maximum of 570nm.
Six days following the formation of the AVL, CM-
DiI–labeled EPCs (2106 cells in 0.2mL sterile saline) were
injected into the systemic circulation of the rats via an in-
tracardiac injection.19 The animals were anesthetized with an
induction dose of 4% halothane (AstraZeneca, North Ryde,
NSW, Australia) in 4 L=min O2.
Histomorphometry
Tissue from each chamber was sliced coronally into 5–8
slices and processed for paraffin embedding (one slice was
reserved for RNA analysis, the remaining slices (4–7) were
processed for histology). The chamber entrance (where the
recipient artery and vein entered the chamber) was considered
the front of the chamber, and vertical (top of construct [adja-
cent to chamber lid] to base of construct [lying on chamber
base]) slices (1–2mm thick) were cut from the chamber en-
trance to the opposite side of the construct. Tissue slices for
histology were placed cut surface down in a single histology
block mold for paraffin embedding. It was this coronal slice
surface that was microtome sectioned for 5-mm sections for
subsequent counting=histomorphometric assessment. This
sampling and sectioning technique was standard for all AVL
constructs. Five-micron-thick sections of all tissue slices=
Table 1. Experimental Groups
Infusion
pump
Protein
carrier
CXCL12 EPC
injection
Group 1 H
Group 2 H H H
Group 3 H H H H
Group 4 H H H
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construct (i.e., 4–7 entire sections per construct, every construct
was examined) were stained with toluidine blue or hema-
toxylin and eosin (H&E), and morphometric analysis of the
H&E stained tissue was carried out using the Computer As-
sisted Stereology Toolbox (CAST) system (Olympus, Den-
mark). The system was set to systematically and randomly
sample an overall fraction of 12% of the entire chamber section
using the10 objective with a grid of 9 points. (Observer, J.
Simcock, was blinded to tissue identity.) It was determined
whether each point fell on the AVL, new fibrovascular tis-
sue, fibrin, or fibrin-containing white blood cells (WBCs).
In calculating volume proportions of tissue components,
the entire construct is given a value of 1. The volume pro-
portion for each tissue component of each construct was
determined by dividing the total points falling over that
particular tissue component in every section counted for that
construct, by the total points counted (including all tissue
components) for that construct.20 These data are presented
as mean tissue volume proportions standard error of the
mean (SEM) in Figure 3a for all constructs in each group. In
addition, within the fibrin compartment only of the con-
struct, the volume proportion of the WBC (leucocyte) com-
ponent was determined by counting the number of points
falling on the WBCs infibrin in all sections of a construct and
dividing this figure by the total number of points falling on
total fibrin (with and without WBCs) in all sections of the
same construct. These data are presented as mean volume
proportion of WBCs in fibrin (SEM) in Figure 3b.
Fluorescent microscopy
Ten-micron-thick sections from the same paraffin blocks
(including 4–7 tissue sections from each construct) were
dewaxed and hydrated in sequential graduated ethanol.
Nuclear counterstaining was performed with 6-diaminido-
2-phenylindole (DAPI) (#D1306; Molecular Probes, Invitrogen,
MountWaverley, Victoria, Australia).When bound to dsDNA,
this stain has an excitation maximum of 358nm and an emis-
sion maximum of 461 maxima. For staining, 300mL of 0.1mM
DAPI diluted in PBS was placed on each hydrated section for
1min. Itwas removedwith three PBSwashes and coverslipped
with fluorescent mounting medium (Dako, Carpintaria, CA).
These slides were stored at room temperature in the dark.
The tissue was viewed with the40 magnification objec-
tive in a systematic fashion across all chamber slices; that is,
the entire section area from every section of every construct
(4–7 sections=construct) was examined in a systematic fash-
ion. The observer ( J. Simcock) was blinded to the identity of
the sections. Individual CM-DiI–stained cells were identified,
and their number was recorded per slice of tissue.
Immunohistochemistry
Visualization of vascular endothelium was achieved by
immunohistochemical staining with biotinylated Griffonia
simplicifolia lectin (rat lectin, #B1105; Vector Labs, Burlin-
game, CA) as described previously.5,21
To determine the nature of the mononuclear cell popula-
tion within the AVL tissue, immunohistochemical staining
with ED1 (mouse anti-rat CD68 IgG, #MCA341R; Serotec,
Oxford, UK), a marker of activated rat macrophages,22 was
performed as described previously.5
The entire area of all tissue sections available from each
construct (4–7 sections=construct) was viewed for both lectin
labeling and ED1 labeling to determine the vascularity and
macrophage infiltration into each construct. The observer
( J. Simcock) was blinded to the identity of the sections dur-
ing this assessment.
RNA extraction
RNA was extracted from a slice of AVL tissue taken from
each construct using TriReagent (Molecular Research
Center Inc., Cincinnati, OH) under sterile conditions fol-
lowing manufacturer’s instructions. RNA was purified using
the NucleoSpin RNA II kit (Macherey-Nagel, Duren, Ger-
many) with mini spin columns according to the manufac-
turer’s instructions. RNA concentration and purity was
determined for each sample using the Nanodrop spectro-
photometer (ND-1000, V 3.1.0; Nanodrop Technologies,
Wilmington, DE).
Quantitative RT-PCR
Quantitative RT-PCR was performed to determine the
RNA levels of CXCL1, CXCL12, and VEGF. RNA (100ng)
was reverse transcribed to cDNA using the Thermoscript
Table 2. Reverse Transcriptase Primers (PROLIGO Primers and Probes, Boulder, CO)
Name Sequence (50 to 30)
RnCXCL1RT CAGTGGCAGG GAT TCACTTC AAGAA
RnCXCL12RT CGGGTCAATG CA CACTTGTC TGTT
RnVEGFRT CGCACTCCAG GGCTTCATCA TT
RnL32RT GCTGTGCTGC TCTTTCTACG ATGGCTTTT
Accession no. Name Sequence (50 to 30)
NM_030845 50RnCXCL1 CAGTGGCAGG GATTCACTTC AAGAA
30RnCXCL1 CCTGGCGGCA TCACCTTCAA A
NM_022177 50RnCXCL12 GTCGCCAGAG CCAACGTCAA A
30RnCXCL12 GGCACAGTTT GGAGTGTTGA GGATTTT
NM_031836 50RnVEGF CACGACAGAA GGGGAGCAGA AA
30RnVEGF GCACACAGGA CGGCTTGAAG A
NM_013226 50Rn L32 CAGGGTGCGG AGAAGA TTCA AGGG
30Rn L32 CTTAGAGGAC ACATTGTGAG CAATC
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RT-PCR system (Invitrogen) and the GeneAmp PCR system
(Model 2400; Perkin Elmer, Wellesley, MA) using gene-
specific priming (reverse primers shown in Table 2). The
product was made up to 100mL with diethylpyrocarbonate
(DEPC)-treated water to give a cDNA concentration of ap-
proximately 1ng=mL.
Quantitative RT-PCR was performed on an ABI Prism
5700 Sequence Detection System (Perkin-Elmer Applied Bio-
systems, Rowville, Victoria, Australia) on cDNA generated
from the equivalent of 2 ng of RNA in 10mM Tris-HCl (pH
8.0), 2.5mMMg(OAc)2, 50mM KCl, 200mM dNTPs, 1=40,000
dilution of SYBR Green I (Molecular Probes, Invitrogen),
1 ng=mL 6-carboxy-X-rhodamine (6-ROX) (Molecular Probes,
Invitrogen), 8% DMSO, 200 nM primers, and 0.625U Ampli-
Taq Gold polymerase (Applied Biosystems, Scoresby, Vic-
toria, Australia) per 25mL reaction. Reaction conditions were
958C for 10min followed by 50 cycles of 958C for 15 s and
608C for 1min. Melt curve analysis was performed at the
end of each run from 608C to 958C to ensure a single PCR
product.
Statistical analysis
Data were analyzed using analysis of variance (ANOVA)
on SPSS for Windows v15.0 (SPSS, Chicago, IL). Where
possible, two-way ANOVA was used with a Tukey’s post hoc
test where appropriate. Alpha was set at 0.05. For counts of
EPC per tissue slice where numbers were small, an exact
Kruskal–Wallis test was used (StatXact v4.0.1, Cytel Soft-
ware, Cambridge, MA) for an overall p-value with an exact
Wilcoxon–Mann–Whitney test for direct comparison be-
tween groups.
Results
There was consistency within individual groups regarding
macroscopic appearance, general histological architecture,
macrophage infiltration, vascularity, and DiI-labeled EPC
occurrence in constructs receiving the same treatment. The
data relating to each of these assessments for each group
appear in the following Result’s sections.
Gross appearance and AVL patency
The AVL of all constructs was patent at harvest, and the
chamber contents were healthy and showed no significant
difference in chamber weight or volume displacement be-
tween those treated with CXCL12 or not. Mean construct
weights for all groups were between 0.250 0.019 g and
0.305 0.023 g (mean SEM), with the CXCL12 infused
groups the heaviest (over 0.3 g in each case) at both time
points. Mean construct volume varied between 0.228
0.016mL and 0.282 0.02mL. Constructs that received
CXCL12 infusions demonstratedmacroscopically the presence
of a white infiltrate in the external cuff of fibrin that was not
apparent in chambers not infused with CXCL12 (Fig. 1e,f ).
Morphology=morphometry
New fibrovascular tissue growth. All groups showed
rapid growth of healthy fibrovascular tissue from the AVL
into the large fibrin clot that initially surrounds the AVL. At
FIG. 1. (a) Diagram illus-
trating the relationship of the
pump to the chamber con-
struct. (b) Diagram illustrat-
ing the experimental design.
(c) The Alzet minipump. (d)
Photograph of the chamber
and pump implantation site in
the groin and flank, respec-
tively. L, leg; white arrow in-
dicates pump catheter
entering chamber; white dot-
ted arrow indicates chamber
construct. Black arrow at top
of figure indicates the bump
in the flank, which is the
pump underneath the skin.
(e, f) Representative macro-
scopic photographs of 8-day
AVL constructs (dotted ar-
row) at harvest that received
an infusion of carrier protein
only (e) or received a CXCL12
infusion (f). The CXCL12-infused tissue shows an extensive leucocyte infiltrate (*) in the fibrin clot. Arteriovenous pedicle,
black arrow; infusion catheter, white arrow. Color images available online at www.liebertonline.com=ten.
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8 and 13 days all constructs demonstrated a cuff of new
fibrovascular tissue (Fig. 2a–d, zone I) around the AVL. The
most mature tissue was adjacent to the AVL adventitia,
whilst an immature proliferative zone (Fig. 2a, arrow) in
which new capillaries were forming was observed adjacent
to and radiating into the more peripheral fibrin clot (Fig. 2a,
d). In all constructs, outside the new tissue was a hemor-
rhagic zone (Fig. 2a–d, zone II), and most peripheral was the
fibrin clot (Fig. 2a–c, zone III). In all CXCL12-treated con-
structs an additional zone of leucocyte infiltration was evi-
dent between zones II and III (Fig. 2c, d).
Morphometric determination of the volume proportion of
the original AVL was similar across all groups (mean SEM;
AVL proportion was between 0.058 0.016 and 0.020
0.004; Fig. 3a), and no significant difference was observed
between groups. At 13 days, more fibrovascular tissue had
developed than at 8 days regardless of treatment (Fig. 3a).
The mean new tissue proportion at 13 days was approxi-
mately 0.6 of the whole construct, but was only 0.35–0.40 at 8
days. More new tissue had formed in the groups that had
been treated with CXCL12 infusion; however, this difference
was not significant (Fig. 3a). In each case the new tissue
formed at the expense of the fibrin component—the pro-
portion of which declined significantly between 8 and 13
days, regardless of treatment ( p¼ 0.002). The mean fibrin
component at 8 days was approximately 0.55–0.60 of the
whole construct, but at 13 days the fibrin component was
approximately 0.25–0.30 of the whole construct (Fig. 3a).
WBC infiltrate. The most obvious difference in
the CXCL12-treated tissue compared to untreated was the
large number of WBCs, including neutrophils and macro-
phages. This was particularly obvious in the peripheral fibrin
clot surrounding the new tissue where an obvious band was
apparent (Fig. 2c, d). In the proliferative zone, increased
numbers of leucocytes were also observed. The leucocytes
were predominantly neutrophils. They included immature
neutrophils in the proliferative zone and mature neutrophils
in the adjacent fibrin, many of which demonstrated evidence
of necrosis with fragmented nuclei (Fig. 4a). There were large
numbers of ED1-positive macrophages within the immature
fibrovascular tissue in CXCL12-treated AVL tissue (Fig. 4a,
b). These were more numerous in CXCL12-treated tissue
than in nontreated tissue.
Using the fibrin clot as the reference compartment, the
proportion of fibrin volume that was infiltrated by leucocytes
was quantified by point counting. Statistical analysis by two-
way ANOVA (time and treatment) showed no significant
difference between the two time points ( p¼ 0.9) but signifi-
cant differences between treatment groups ( p< 0.0005), the
addition of CXCL12 increasing the infiltrate significantly from
the BSA group ( p¼ 0.004) and the addition of EPCs increasing
the proportion again ( p¼ 0.021) (Tukey’s post hoc) (Fig. 3b).
Vascularity. Lectin immunohistochemistry clearly dem-
onstrated large numbers of new endothelial-lined blood
vessels in all groups. Vascular maturity was also similar,
with all groups demonstrating arteriole development at 8
days and beyond. Both control and CXCL12-treated tissue
were highly vascular, and no difference in overall vascularity
was apparent between groups (Fig. 5b, c).
Large endothelium-lined vascular channels were evident
in CXCL12-treated tissue at 8 days (Fig. 5a). These channels
were smaller and less numerous at 13 days. Vascular chan-
nels were not apparent in untreated tissue (compare Fig. 2b
and c). Lectin labeling indicated that they were mainly en-
dothelial lined; however, some channels did not appear to be
lined with endothelium, particularly when located near the
proliferative zone.
RNA analysis
RT-PCR results were normalized in each sample against a
housekeeping gene (ribosomal L32). Greater RNA levels are
expressed numerically as a smaller negative number (dCt)
and graphically as a shorter bar. RNA expression of the
FIG. 2. Representative figures of coronal histological sections
through the AVL construct. (a) An 8-day construct demon-
strating the vein graft lumen (L) and the tract of the infusion
pump catheter (P), new fibrovascular tissue (zone I), prolifer-
ative zone (arrow), and associated hemorrhage into the fibrin
matrix (zone II) (H&E; scale bar¼ 2mm). (b) Eight-day con-
struct following infusion of carrier protein only. New fibro-
vascular tissue (zone I), hemorrhage into the fibrin (zone II),
and the fibrin matrix (zone III) (H&E; scale bar¼ 1mm). (c)
Eight-day construct following infusion of CXCL12 protein.
New fibrovascular tissue (zone I), proliferative zone with as-
sociated hemorrhage (zone II), and the fibrin matrix (zone III).
Asterisk (*) indicates band of neutrophil infiltrate in the inner
fibrin clot [not seen in (b) BSA infused construct]—close to the
proliferative zone and vascular channels. Arrow indicates
vascular channels clearly seen in the CXCL12-infused construct
that are not evident in BSA-infused construct (b) (H&E; scale
bar¼ 1mm). (d) Higher power of 8-day construct following
infusion of CXCL12 protein showing new fibrovascular tissue
(zone I), proliferative zone with new capillary development
(arrow), hemorrhagic zone (II), and band of neutrophil infil-
trate (*) (H&E; scale bar¼ 200mm). Color images available
online at www.liebertonline.com=ten.
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CXCL12 gene in AVL tissue from all groups at both 8 days
and 13 days was high compared to other gene products that
have been measured in our chamber (e.g., transforming
growth factor b and VEGF; Z. Lokmic, personal communi-
cation). VEGF and CXCL1 RNA levels appeared higher in the
CXCL12-infused groups than in the noninfused groups
at both time points measured (Fig. 6); however, statisti-
cal analysis by one-way ANOVA showed no significant
differences in the levels of CXCL1, CXCL12, and VEGF, be-
tween the CXCL12 infused and non-CXCL12-infused tissue.
FIG. 3. (a) Volume propor-
tion (mean SEM) of AVL,
new fibrovascular tissue that
grows from the AVL, and fi-
brin scaffold, for all groups
after either 8 or 13 days.
*Statistical analysis by two-
way ANOVA demonstrated a
significant decrease in fibrin in
all 13-day groups compared to
8-day groups. (b) Volume
proportion (mean SEM) of
the fibrin matrix containing
predominant WBC infiltrate.
*,#Statistical analysis by two-
way ANOVA showed a
significant increase in WBC
infiltrate with CXCL12
(*p¼ 0.004 compared with
BSA group) and the addition
of EPCs further increasing the
proportion (#p¼ 0.021;
Tukey’s post hoc).
FIG. 4. Representative fig-
ures of ED1 immunohisto-
chemical labeling of an 8-day
AVL construct receiving a
CXCL12 infusion. (a) A high
concentration of activated
macrophages (black arrow) is
apparent in the proliferative
zone (II) lying between ma-
turing fibrovascular tissue (I)
and neutrophils in the adja-
cent fibrin clot (*). White ar-
row indicates pyknotic
neutrophil nuclei (scale
bar¼ 200 mm). (b) Higher
power micrograph of acti-
vated macrophages (arrows)
in the proliferative zone (scale
bar¼ 50mm). Color images
available online at www
.liebertonline.com=ten.
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EPC counts
CM-DiI–labeled EPCs were readily visualized within the
AVL tissue by fluorescence microscopy, and every animal that
was infused with labeled EPCs demonstrated EPCs within the
construct, although the numbers varied according to whether
or not the chamber was infused with CXCL12. Labeled EPCs
were seen both within the leucocyte infiltrate of the fibrin and
within the newly developed fibrovascular tissue (Fig. 7a, b) in
all tissue sections of constructs that received CXCL12, al-
though they were not observed as part of the endothelial
lining of blood vessels, other than in the femoral vein wall in
one specimen. Occasional cells were seen in all control
chambers (no pump and BSAþEP), but their numbers were
significantly less than in chambers receiving CXCL12. Fewer
labeled cells were seen within the tissue that received the
carrier protein (0.1% BSA) only (Fig. 7c). Differences in cell
numbers between groups were significant ( p< 0.0005; exact
Kruskal–Wallis). The number of DiI-labeled EPCs in CXCL12-
infused chambers at 8 days ( p¼ 0.03) and 13 days ( p¼ 0.008)
was significantly higher than controls. Fewer EPCs were seen
in the CXCL12 group when harvested at 7 days after EPC
injection (total 13 days) as opposed to 2 days after EPC in-
jection (total 8 days) ( p¼ 0.03).
Discussion
Tissue engineering implies the creation of whole tissue
consisting of cells, matrix, and a blood supply. Bringing
the three components together in the same place at the
same time is one of the central challenges of tissue engi-
neering. Either cells are combined with matrix in a bioreac-
tor and the blood supply must grow into the construct once
it is placed in the body with an inevitable period of hypoxia,
or a matrix is vascularized in the body and cells must be
added to an already fixed structure. One novel way to deal
with this conundrum is to build a vascularized structure, and
deliver new pluripotent or specialized cells to it via the
growing microcirculation. Such a strategy will require a
method of attracting specific cell types into the growing
structure.
This study demonstrates that an angiogenic chemokine
(CXCL12) can be successfully infused into a growing tissue-
engineered construct to exert bioactive effects, including
significantly increased EPC homing, a concomitant influx
of leukocytes predominantly neutrophils into the fibrin
clot, and of macrophages into the growing tissue. None of
these increased cell infiltrations had any effect on normal
FIG. 5. Vascularity of constructs. (a) Representative fig-
ure of toluidine blue staining demonstrating numerous
endothelium-lined vascular channels (*) between new ma-
turing fibrovascular tissue (I) and the proliferative zone (II)
in an 8-day CXCL12-infused construct (scale bar¼ 100 mm).
(b, c) Representative figures of lectin labeling following (b) a
control (0.1% BSA) infusion and (c) a CXCL12 infusion. The
staining demonstrates that both tissues were highly vascular
(arrows) (scale bars¼ 100mm). Color images available online
at www.liebertonline.com=ten.
FIG. 6. RT-PCR for RNA
expression of CXCL1,
CXCL12, and VEGF in AVL
tissue. There was no
significant change in steady-
state mRNA levels (mean
 SEM) for all three genes in
the CXCL12-infused tissue
although a trend to higher
levels is indicated.
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angiogenesis and connective tissue growth and maturation
that occurs in the AVL construct up to 13 days. CXCL12 has
previously been associated with increased numbers of lym-
phocytes23; however, this was not seen in our tissue, pre-
sumably because nude rats are T-lymphocyte deficient.
Postnatally, the main function of CXCL12 is leucocyte
homeostasis. Both mature and progenitor hematopoietic cells
are controlled by the CXCL12=CXCR4 axis. As well as
playing a central role in the interactions of hematopoietic
stem cells, lymphocytes, and developing neutrophils in the
bone marrow, the CXCL12=CXCR4 axis has recently been
shown to be critical in circulating neutrophil homeostasis. In
particular, CXCR2-binding inflammatory chemokines release
neutrophils from the bone marrow by reducing CXCR4 bone
marrow expression.24
The CXCL12=CXCR4 axis has effects both on endoge-
nous angiogenesis (either directly or via certain secondary
cytokines, e.g., VEGF-A) and on vasculogenesis (via EPC
mobilization and homing). The mechanism by which circu-
lating EPCs home to areas of neovascularization such as
that occurring in the AVL construct is a CXCL12=CXCR4-
dependant process requiring both CXCR4 surface receptor
on the EPCs and CXCL12 on the luminal surface of the en-
dothelium.11,15 CXCL12 induces a rapid but transient acti-
vation of integrins on the circulating EPCs, thus facilitating
the binding of the cells to endothelium and their egress from
the circulation.25
There are many reported secondary effects of CXCL12 as
an angiogenic chemokine, including increasing expression
of angiogenic cytokines. CXCL12 is proinflammatory and
proangiogenic. The coordination of angiogenesis and inflam-
mation is a result of the ability shared by endothelial cells and
leucocytes to respond to chemokines via their specific recep-
tors.26,27 This study demonstrates the combined effects of
CXCL12 on the recruitment of EPCs and macrophages and
neutrophils to the chamber. These cells home down CXCL12
gradients via the CXCR4 receptor, and the addition of exoge-
nous CXCL12 into the chamber ‘‘bioreactor’’ increases that
gradient toward the chamber and therefore promoted the re-
cruitment of all three cell types. Certainly, macrophages and
neutrophils produce more angiogenic factors that may have
influenced the angiogenesis in the chamber although no in-
crease in angiogenesis was observed in CXCL12-treated
chambers. It should also be acknowledged that the normal
‘‘untreated’’ chamber growth is highly angiogenic and always
includes many macrophages. There was no obvious tissue
death in the new tissuewithin the chamber; despite the increase
inmacrophages. However, there was significant necrotic death
in neutrophil infiltrates within the fibrin. Thus most of the in-
vading neutrophils die soon after reaching the chamber and
may have very little influence on other cell movements.
VEGF can be produced by many of the cells involved in the
AVL construct’s angiogenic system, including endothelial
cells, macrophages, and neutrophils.28,29 The role of CXCL12
FIG. 7. Representative figures of CM-DiI–
labeled CD34þ cells 2 days following injection.
CM-DiI–labeled cells (arrows) were seen
within new fibrovascular tissue (a) and within
leucocyte infiltrate (b) within the fibrin clot
(DAPI nuclear counterstaining, dual exposure
image, scale bars¼ 50mm). (c) Number of CM-
DiI–labeled cells (mean SEM) per 10-mi-
cron-thick AVL tissue section. Asterisk (*) in-
dicates that differences between groups are
significant ( p< 0.0005, exact Kruskal–Wallis
test) with the two CXCL12 groups differing
significantly (8 days, p¼ 0.03; 13 days,
p¼ 0.008) from the control groups. The decline
in numbers of cells from the 8-day group to
the 13-day group was also significant
( p¼ 0.03). Color images available online at
www.liebertonline.com=ten.
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is supported by a regulatory loop between VEGF-A and the
CXCL12=CXCR4 axis. CXCL12 upregulates VEGF-A pro-
duction, and VEGF-A upregulates CXCR4 expression, thus
generating an amplification circuit crucially influenced by
hypoxia.7 We have previously demonstrated that the AVL
chamber is hypoxic between days 3 and 14.5,30 This level of
hypoxia was not effective in promoting EPC recruitment,
whilst a specific infusion of CXCL12 as demonstrated in this
study provided a localized target to circulating CXCR4þ cells.
CXCL12-infused tissue demonstrated large, irregular
vascular channels not seen in untreated chambers5 previ-
ously. These channels may either have been generated due to
the chemokine itself or, more likely, by the significant
numbers of additional leukocytes attracted to the chamber
circulation, which then underwent diapedesis into the new
tissue and surrounding fibrin clot. These spaces did not
persist following the end of the infusion and did not appear
to exert any adverse effects on the tissue. We did not see
irregular large vascular channels or increased numbers of
leucocytes in tissue where only the carrier protein solution
was infused, attributing these effects specifically to CXCL12
rather than a nonspecific inflammatory response to the car-
rier protein, catheter, or pump.
Infusion of CXCL12, an angiogenic chemokine, may be
expected to increase vascularity in the growing tissue.
Unlike the studies of subcutaneous CXCL12 injection that
resulted in increased vascularity,7 we were unable to dem-
onstrate any marked increase in vascularity in CXCL12-
treated constructs. This may be due to the fact that, unlike
mature subcutaneous tissue, the tissue growing from the
AVL was already highly vascular,5 considerably more so
than normal skin or healing skin wounds5,21 and that there
was therefore limited capacity for it to increase. The fact that
the AVL construct tissue was highly angiogenic could also
explain why the CXCL12 infusion did not result in a signif-
icant increase in VEGF RNA expression in the tissue. It is
possible that since the level of VEGF expression was already
high in the AVL tissue, there may have been limited capacity
for it to increase. The lack of statistical significance in the
trend toward increased VEGF RNA expression could also be
due to variations in measurement due to tissue heterogene-
ity, as reflected in the relatively large error margins.
In addition to the leucocyte infiltrate described above, EPCs
were observed to spontaneously home to the untreated
chamber tissue in very small numbers; however, human EPCs
homed in significantly increased numbers to the growing
construct tissue in response to the CXCL12 infusion. This
finding is consistent with the successful use of CXCL12 to
augment EPC homing in ischemic models.31 There are a num-
ber of differences between the two models, including that the
ischemic limb skeletal muscle has lower vascularity than the
AVL construct and so interventions in the ischemic limbmodel
aim to enhance neovascularization. It also has an existing ex-
tensive capillary network through which EPCs may home to
the tissue immediately following onset of ischemia. In contrast,
our model of VTE does not produce an abundant capillary
network until 5–14 days.5 Therefore, the AVLmodel required a
CXCL12 infusion over time rather than a single injection. Pre-
liminary studies showed that no EPCs homed to the AVL until
the capillary network had developed (data not shown).
Enhancing the vascularity of the AVL engineered tissue was
not a major objective of this study, rather enhancing EPC re-
cruitment to the AVL tissue was undertaken with the aim that,
in future experiments, a specific differentiation signal could be
introduced into the early chamber tissue. This study demon-
strates that CXCL12may be utilized to enhance EPC homing to
rapidly growing tissue. CXCL12 has specific transient histo-
morphologic effects on the tissue, but has no detrimental effects
on either quantity or quality of the tissue grown.
The use of the osmotic pump with the AVL construct is a
major advancement. This is the first time the AVL construct
has been manipulated whilst in vivo to modify the growth of
the construct. At the moment, CXCL12 is required to be in-
fused for a number of days to produce a response in terms of
increased EPC homing. Although desirable, the technology
to incorporate CXCL12 into a controlled drug release system
within the construct is currently not available, but one can
envisage advancements in minipumps and=or drug delivery
systems and=or matrices that would allow this in the future,
not just for the administration of CXCL12, but for any
number of chemicoattractant, proliferative, or differentiation
factors, depending on the tissue being engineered.
In summary, in VTE, exogenous CXCL12 significantly
enhanced homing of EPCs to an angiogenic site developing
around an AVL inserted in a tissue engineering chamber,
thus enabling this population of precursor cells to be used in
future experiments to carry a differentiation message spe-
cifically to the engineered construct.
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